NAD+ is a coenzyme, not a peptide, although it is sold alongside them. It takes part in oxidation and reduction reactions and in energy metabolism, in DNA repair and in mitochondrial biogenesis, and cellular levels fall with age and under metabolic stress. Sold as research material, not as a medicine.
Bio-Peptide, 1000 mg
300,00 złAdd to cart5 in stock (can be backordered)
What is in the vial
One vial holds 1000 mg of lyophilised powder from Bio-Peptide. It is the only NAD+ product in this catalogue, so there is no brand comparison to make here; what differs between suppliers of this compound is purity and the certificate of analysis, not the molecule.
The powder has no concentration of its own. Concentration is decided by the amount of water added: 10 ml of bacteriostatic water in a 1000 mg vial gives 100 mg per millilitre, 20 ml gives 50 mg per millilitre. The arithmetic and the conversion into insulin syringe units are set out in the guides on reconstitution and on syringe units.
What human studies show
Oral forms have poor bioavailability because they are metabolised in the digestive tract. That is why intravenous infusion is described in the literature as the only established route for raising NAD+ clinically.
In a pilot study using a six-hour intravenous infusion, no change in plasma NAD+ or its metabolites appeared during the first two hours. The changes came later in the infusion. That single finding says more about this compound than most marketing copy: whatever happens, it does not happen quickly.
A comparative study published in 2026 comparing intravenous NAD+ with nicotinamide riboside reported moderate to severe gastrointestinal symptoms, a faster heart rate and chest tightness in the NAD+ group. The nicotinamide riboside group had milder symptoms, mostly tingling and small cramps. NAD+ infusions in that study lasted 97 minutes on average, nicotinamide riboside infusions 37 minutes. The same study found no significant changes in liver enzymes, inflammatory markers, kidney parameters or thyroid function.
What the studies do not show
Every human study cited above used a supervised intravenous infusion. Dosing schedules for self-administered subcutaneous injections circulate widely on forums and in old shop descriptions, including our own before this page was rewritten. They do not come from clinical research and we do not repeat them.
Nothing here says NAD+ slows ageing, restores energy or repairs anything in a person. Those claims are made in advertising, not in the studies above.
How it sits among the other compounds here
NAD+ is listed with GHK-Cu and glutathione in the skin and longevity group, because that is how buyers look for them, not because they share a mechanism. GHK-Cu is a tripeptide, glutathione a tripeptide antioxidant, NAD+ a coenzyme. What the human evidence for the three actually supports is compared in the guide on NAD and glutathione injections.
Verification and delivery
Every vial carries a code under the hologram; how to check it, and what a certificate of analysis should contain, is described in check your product. We ship within Poland and abroad; outside Poland the cost is quoted individually, depending on weight and destination country. Payment and delivery details are on the shipping and payments page.
Questions
Is NAD+ a peptide?
No. It is a coenzyme built from two nucleotides. It is sold in peptide shops because the buyers overlap, not because the chemistry does.
Why is it sold as powder rather than a ready solution?
Lyophilised powder keeps far longer than a solution and travels without a cold chain. The solution is prepared when it is needed, and from that point storage rules change: see the guide on storing peptides.
Can you give me a dosing protocol?
No. There is no dosing schedule for self-administered NAD+ that comes from a clinical study, and we do not invent one. The studies we cite used supervised infusions in a clinical setting.
How is it different from nicotinamide riboside?
Nicotinamide riboside is a precursor: the body converts it into NAD+. In the 2026 comparison the two were given intravenously side by side, and the riboside group reported milder symptoms and much shorter infusions, 37 minutes against 97.